Since 1990, when retrovirus was first applied for clinical gene therapy of adenosine deaminase (ADA)-deficient severe combined immunodeficiency (ADA-SCID),292 viral vectors for the delivery of nucleotide agents have rapidly developed. The gene discussed is ADA; the disease is severe combined immunodeficiency.